⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7012758 | 0.76 | — | — | |
| SCHEMBL7014553 | 0.70 | — | — | |
| SCHEMBL8701143 | 0.62 | ALDH1A1 (0.32) | — | |
| SCHEMBL5628044 | 0.60 | — | — | |
| SCHEMBL9790462 | 0.59 | KDM1A (0.46) | — | |
| SCHEMBL9790470 | 0.59 | KDM1A (0.46) | — | |
| SCHEMBL9790466 | 0.59 | KDM1A (0.46) | — | |
| SCHEMBL8849626 | 0.59 | CYP1A2 (0.33) | — | |
| SCHEMBL5232516 | 0.58 | MAPT (0.37) | — | |
| Hydrochloric Acid SCHEMBL9790500 | 0.58 | KDM1A (0.44) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6127389-A | TREATMENT OF HYPERTENSION, RENAL DISEASES, HEART FAILURE, HYPERTENSION, MENIERE'S DISEASE, PERIPHERAL AND CEREBRAL CIRCULATORY DISORDERS, CLIMACTERIC DISTURBANCE, RETINOCHOROIDAL CIRCULATORY DISORDERS, MYOCARDIAL ISCHEMIA | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2000-10-03 | — | — | US | disclosed |
| US-6015818-A | TREATING KIDNEY, BRAIN, AND CARDIOVASCULAR DISORDERS; HYPOTENSIVE AGENTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2000-01-18 | — | — | US | disclosed |
| EP-0861243-A1 | HETEROCYCLIC COMPOUNDS AS BRADYKININ ANTAGONISTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1998-09-02 | — | — | EP | disclosed |
| WO-1997011069-A1 | HETEROCYCLIC COMPOUNDS AS BRADYKININ ANTAGONISTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1997-03-27 | — | — | WO | disclosed |